Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™.
The company expects to receive its final Australian cannabis licenses and permits in the near-term.
Definitive feasibility study and permitting approvals both on-track for year-end 2019.
THC has partnered with a Malaysian bio-tech firm to deliver medicinal cannabis products.
Shares in the company are trading at 52.5 cents, a premium to the 50-cent offer price.
Shareholders can acquire shares at 50 cents, being a discount to the last price of 56.5 cents.
This purchase follows recent buying from the company’s board’s chairman.
This follows chairman Geoff Starr’s on-market share purchases last month.